Mark D DeBoer1, Stephanie L Filipp2, Matthew J Gurka3. 1. Department of Pediatrics, Division of Pediatric Endocrinology, University of Virginia, PO Box 800386 Charlottesville, VA, 22908, United States. Electronic address: deboer@virginia.edu. 2. Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, 32608, United States. Electronic address: sfilipp@ufl.edu. 3. Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, 32608, United States. Electronic address: matthewgurka@ufl.edu.
Abstract
BACKGROUND AND AIMS: Many traditional assessments of risk for coronary heart disease (CHD) and diabetes require laboratory studies performed after an 8-h fast. We assessed whether metabolic-syndrome (MetS) severity would remain linked to future CHD and diabetes even when assessed from non-fasting samples. METHODS AND RESULTS: Participants in the Atherosclerosis Risk in Communities study were assessed at 4 visits and followed for 20-years of adjudicated CHD outcomes. We used Cox proportional-hazard models (for 20-year CHD outcomes) and logistic regression (for 9-year diabetes outcomes) to compare incident disease risk associated with a race/ethnicity-specific MetS-severity Z-score (MetS-Z) calculated in participants who were fasting (≥8 h) or non-fasting. All analyses were adjusted for sex, race, education, income and smoking. MetS Z-scores were overall similar between participants who were always fasting vs. those non-fasting at Visits 1-3 (all values -0.1 to 0.4), while MetS-Z for participants who were non-fasting at Visit-4 were higher at each visit. Baseline MetS-Z was linked to future CHD when calculated from both fasting and non-fasting measurements, with hazard ratio (HR) for fasting MetS-Z 1.53 (95% confidence interval [CI] 1.42, 1.66) and for non-fasting 1.28 (CI 1.08, 1.51). MetS-Z at Visit-1 also remained linked to future diabetes when measured from non-fasting samples, with odds ratio for fasting MetS-Z 3.10 (CI 2.88, 3.35) and for non-fasting 1.92 (CI 1.05, 3.51). CONCLUSIONS: MetS-Z remained linked to future CHD and diabetes when assessed from non-fasting samples. A score such as this may allow for identification of at-risk individuals and serve as a motivation toward interventions to reduce risk.
BACKGROUND AND AIMS: Many traditional assessments of risk for coronary heart disease (CHD) and diabetes require laboratory studies performed after an 8-h fast. We assessed whether metabolic-syndrome (MetS) severity would remain linked to future CHD and diabetes even when assessed from non-fasting samples. METHODS AND RESULTS:Participants in the Atherosclerosis Risk in Communities study were assessed at 4 visits and followed for 20-years of adjudicated CHD outcomes. We used Cox proportional-hazard models (for 20-year CHD outcomes) and logistic regression (for 9-year diabetes outcomes) to compare incident disease risk associated with a race/ethnicity-specific MetS-severity Z-score (MetS-Z) calculated in participants who were fasting (≥8 h) or non-fasting. All analyses were adjusted for sex, race, education, income and smoking. MetS Z-scores were overall similar between participants who were always fasting vs. those non-fasting at Visits 1-3 (all values -0.1 to 0.4), while MetS-Z for participants who were non-fasting at Visit-4 were higher at each visit. Baseline MetS-Z was linked to future CHD when calculated from both fasting and non-fasting measurements, with hazard ratio (HR) for fasting MetS-Z 1.53 (95% confidence interval [CI] 1.42, 1.66) and for non-fasting 1.28 (CI 1.08, 1.51). MetS-Z at Visit-1 also remained linked to future diabetes when measured from non-fasting samples, with odds ratio for fasting MetS-Z 3.10 (CI 2.88, 3.35) and for non-fasting 1.92 (CI 1.05, 3.51). CONCLUSIONS:MetS-Z remained linked to future CHD and diabetes when assessed from non-fasting samples. A score such as this may allow for identification of at-risk individuals and serve as a motivation toward interventions to reduce risk.
Authors: Genovefa D Kolovou; Gerald F Watts; Dimitri P Mikhailidis; Pablo Pérez-Martínez; Samia Mora; Helen Bilianou; George Panotopoulos; Niki Katsiki; Teik C Ooi; José Lopez-Miranda; Anne Tybjærg-Hansen; Nicholas Tentolouris; Børge G Nordestgaard Journal: Curr Vasc Pharmacol Date: 2019 Impact factor: 2.719
Authors: Maria Inês Schmidt; Bruce B Duncan; Heejung Bang; James S Pankow; Christie M Ballantyne; Sherita H Golden; Aaron R Folsom; Lloyd E Chambless Journal: Diabetes Care Date: 2005-08 Impact factor: 19.112
Authors: Børge G Nordestgaard; Anne Langsted; Samia Mora; Genovefa Kolovou; Hannsjörg Baum; Eric Bruckert; Gerald F Watts; Grazyna Sypniewska; Olov Wiklund; Jan Borén; M John Chapman; Christa Cobbaert; Olivier S Descamps; Arnold von Eckardstein; Pia R Kamstrup; Kari Pulkki; Florian Kronenberg; Alan T Remaley; Nader Rifai; Emilio Ros; Michel Langlois Journal: Clin Chem Date: 2016-05-27 Impact factor: 8.327
Authors: Matthew J Gurka; Sherita H Golden; Solomon K Musani; Mario Sims; Abhishek Vishnu; Yi Guo; Michelle Cardel; Thomas A Pearson; Mark D DeBoer Journal: Diabetologia Date: 2017-04-04 Impact factor: 10.122
Authors: Mark D DeBoer; Stephanie L Filipp; Solomon K Musani; Mario Sims; Mark D Okusa; Matthew Gurka Journal: Kidney Blood Press Res Date: 2018-04-06 Impact factor: 2.687
Authors: Mohamed A Elhadad; Rory Wilson; Shaza B Zaghlool; Cornelia Huth; Christian Gieger; Harald Grallert; Johannes Graumann; Wolfgang Rathmann; Wolfgang Koenig; Moritz F Sinner; Kristian Hveem; Karsten Suhre; Barbara Thorand; Christian Jonasson; Melanie Waldenberger; Annette Peters Journal: Cardiovasc Diabetol Date: 2021-05-20 Impact factor: 9.951
Authors: Teresa E Daniels; Emily K Zitkovsky; Zachary J Kunicki; Destiny J Price; Abigail L Peterson; Phyllis A Dennery; Hung-Teh Kao; Lawrence H Price; Audrey R Tyrka; Ana M Abrantes Journal: Brain Behav Immun Health Date: 2022-09-19